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On the Road to Recovery psychological
therapy versus treatment as usual for
forensic mental health patients: study
protocol for a randomized controlled
feasibility trial
Lindsey G. McIntosh1,2* , Morag Slesser2, Suzanne O’Rourke2,3 and Lindsay D. G. Thomson1,2
Abstract
Background: On the Road to Recovery (OTRTR) is a brief low intensity group psychological therapy that aims to
improve patients’ insight into their mental disorder and develop adaptive coping skills to help manage distress.
OTRTR is currently delivered in forensic mental health services in Scotland. However, to date, this therapy has not
been evaluated as to its effectiveness or safety for forensic patients.
Methods: This is a parallel-group feasibility randomized controlled trial with single-blind assessments comparing
OTRTR therapy to treatment as usual (TAU) for forensic mental health patients. Fifty participants will be recruited
from high, medium, and low secure forensic mental health services in Scotland. Participants will receive OTRTR for
approximately 12 weeks or continue treatment as usual for 12 weeks. The trial’s primary aims relate to testing the
acceptability and feasibility of key trial procedures that would be necessary for a definitive RCT of OTRTR. The secondary
aims include estimating therapeutic effect sizes on clinical outcomes including insight and coping skills. The study design
also features an adverse event monitoring plan to estimate the safety of OTRTR for participants, as well as use of intensive
longitudinal methods to identify “key ingredients” to the OTRTR therapy protocol.
Discussion: This study will inform the design and sample size for a future full-scale randomized controlled trial (RCT),
which will be conducted to determine the effectiveness of the On the Road to Recovery intervention in improving forensic
mental health patients’ clinical insight and coping skills.
Trial registration: ISRCTN Registry, ISRCTN75126867 registered 27 July 2017
Keywords: Mentally disordered offenders, Feasibility outcomes, RCT, Recovery, Coping ability, Clinical insight,
Psychological intervention
Background
Forensic mental health patients often present with varied
and complex treatment needs relating to their mental
health and offending behavior [1, 2]. Treating these indi-
viduals requires significant involvement of clinical and
forensic psychological practitioners as part of the
multi-disciplinary treatment team. However, the evi-
dence base for psychological interventions with forensic
patients remains severely limited. Previous reviews have
highlighted that a lack of rigorous methodologies, in-
cluding the randomized controlled design, in forensic
mental health evaluations has restricted the synthesis of
effectiveness evidence in this field [2, 3].
Within NHS Scotland, psychological treatment of fo-
rensic patients is guided by the Forensic Matrix (an ad-
dendum to the larger “Matrix,” a guide to delivering
evidence-based psychological therapies in Scotland [4]).
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The Forensic Matrix proposed a model of “stepped care”
[5] for forensic patients. This model acknowledges that
forensic patients often present with complex and endur-
ing problems relating to their risk and offending behav-
iors which require highly specialist and individually
tailored psychological treatment from practitioners with
high levels of training and forensic expertise. However,
they often also have simpler underlying or associated
psychological needs which may respond to less intensive
interventions. According to the Forensic Matrix stepped
care approach, different levels of intervention intensity
can be used to address forensic patients’ needs. For ex-
ample, a forensic patient may require psychological work
aimed at improving their management of basic emotions
(low intensity) before the patient will be able to cope
with the demands of sex-offending treatment (special-
ist/highly specialist). Several psychological interven-
tions which address different common underlying
needs of forensic patients have now been developed
as part of the Forensic Matrix suite of interventions.
There is now a critical need to evaluate the effective-
ness of these therapies.
On the Road to Recovery (OTRTR) is a brief, low
intensity group psychological intervention delivered across
the Scottish Forensic Mental Health Managed Care
Network (“Forensic Network”). The OTRTR protocol was
written in 2011 by a working group of clinical and forensic
psychologists within the Forensic Network. The program
is based on the principles of cognitive behavior therapy
with a focus on compassionate mind training [6]. The core
purpose of OTRTR is to open a dialog about recovery and
instill in patients hope that recovery is possible. It is
intended to be one of the first psychological treatments of-
fered to patients on their journey to recovery from mental
health difficulties, prior to engaging in more demanding
and longer term therapy.
The aim of this study is to determine the feasibility of
conducting an RCT comparing On the Road to Recovery
psychological therapy to treatment as usual (TAU) for
forensic mental health patients. Consistent with the UK
Medical Research Council guidance (MRC) results from
this study will directly inform the decision to undertake
a future definitive RCT of OTRTR [4, 5]. Specifically,
the feasibility RCT will determine:
1. Participant recruitment, consent, and retention rates
2. Acceptability of randomization to treatment condition
3. Acceptability of the OTRTR intervention for patients
4. Safety of the OTRTR intervention for patients
5. Acceptability of intensive longitudinal modeling
procedures, in terms of:
a. The completion rate of standardized recording
forms of the therapy content delivered by OTRTR
therapy facilitators
b. The completion rate of primary clinical outcome
measures weekly during treatment phase
6. Obtain estimates of likely therapeutic effects of
OTRTR for use in sample size calculation of a
future definitive trial. The between-group mean
difference in therapeutic outcomes at the post
treatment assessment, along with the standard
deviation of the outcome for the entire sample,
at baseline will be recorded.
Methods
Design
This study is a feasibility study using a parallel-group
randomized outcome blinded design to compare
OTRTR to treatment as usual (TAU). As a feasibility
study, the primary study aims relate to testing the ac-
ceptability and feasibility of key trial procedures that
would be necessary for a full-scale RCT of this program.
The comparator group will receive treatment as usual.
In this study, 50% of participants will be randomized to
commence OTRTR immediately for approximately
12 weeks. The remaining 50% will engage in TAU for
12 weeks and may complete OTRTR in the future.
Participants will continue their usual access to concomi-
tant therapies and therapeutic activities throughout the
study. Participants will complete a range of self-report
measures and a clinical interview at baseline (T0), post
treatment (T1), and at follow-up (T2), 3-months after
the T1 assessment, with an assessor who will be blind to
participants’ allocation status. Clinical effect sizes will be
estimated using two approaches, at the group level for a
range of clinical outcomes by comparing change from
pre to post treatment and at the individual level for the
two primary outcomes—insight into mental disorder
and use of adaptive coping skills—using intensive longi-
tudinal methods (ILM) [7, 8]. Findings from two large
treatment evaluations, the PEPS trial [9] and Ministry of
Justice’s evaluation of the prison-based Core Sex Of-
fender Treatment Programme [10], demonstrated that
psychological therapies have the potential to cause harm
to patients, a concept which has received little attention
until recently. Accordingly, this study will pilot an ad-
verse event monitoring plan to estimate the safety of
OTRTR for participants.
Following participation in the study, participants will be
offered the opportunity to complete a semi-structured
interview which will gather qualitative information on
their experiences of participating and views on different
aspects of the trial (for instance, randomization, treat-
ment, and assessments).
Study setting
Participants will be recruited and identified from foren-
sic mental health services which are part of the NHS
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Scotland. Services include high, medium, and low secure
inpatient settings as well as community forensic teams.
Sample size
As this study is a feasibility trial, a power calculation to
determine sample size was not undertaken [11]. The
target recruitment for this feasibility trial will be N = 50
(25 in each intervention arm). This figure is consistent
with recommendations for pilot and feasibility studies
and appropriate given the study aims [12, 13].
Inclusion criteria
People meeting inclusion criteria for the study include
(1) males and females aged between 18 to 65 years, (2)
who are receiving treatment under the Mental Health
(Care and Treatment) (Scotland) Act 2003 from a par-
ticipating forensic mental health service, and (3) who are
viewed by their Responsible Medical Officer (RMO) as
capable of providing informed consent and well enough
to participate in the study.
Exclusion criteria
People meeting exclusion criteria for the study include
(1) those with a diagnosis of intellectual disability, (2)
those who are viewed by their RMO as incapable of pro-
viding consent or are too unwell to participate, and (3)
those who have completed On the Road to Recovery in
the prior 3 years.
Identification and recruitment of participants
The study inclusion criteria were selected to match the
broad range who are referred to On the Road to Recov-
ery. Potential participants will be identified by their local
psychological therapies team using the existing local re-
ferral process. The Responsible Medical Officers for each
patient referred to On the Road to Recovery will be con-
sulted on whether their patient has capacity to provide
informed consent. Those without capacity will not be
approached about the research. Potential participants
with capacity to consent will be first informed of the
study by their local psychological therapies team. Subse-
quently, a researcher will meet with these potential par-
ticipants that have expressed an interest to provide them
with further information and obtained informed consent
to participate.
Randomization
Sequence generation and allocation
Participants will be randomly assigned to either OTRTR
or TAU with a 1:1 allocation ratio and varying block size
(4 or 6), using a computer-generated randomization
schedule stratified by site and assessed treatment need at
T0. Participants will be categorized as having low or high
treatment need based on scores on the two primary
clinical outcome measures: the Birchwood Insight Scale
and the Coping Styles Questionnaire. To categorize
participants, we will employ cut-off scores of ≤ 9 (the
cut-off for good versus poor insight following Birchwood
et al. [14]) on the Birchwood Insight Scale and ≤ 37 on
the Coping Styles Questionnaire [15] adaptive coping
index (corresponding to 1 SD below the observed
sample mean for State Hospital patients commencing
On the Road to Recovery in a previous evaluation
(McIntosh, Purcell, O’Rourke, Slesser, Thomson, manu-
script in preparation)). Participants with poor insight
and low adaptive coping skills will be considered to have
high treatment need, and all other participants will be
considered to have low treatment need. This stratum will
be used to equally distribute patients with more acute
needs across the two treatment conditions.
Implementation
Staff of the Forensic Network office will generate the allo-
cation sequence using an online randomization service
(www.sealedenvelope.com). The Forensic Network office
provides a centralized staff group who are knowledgeable
of the participating services (the potential participating
sites are part of the “Forensic Network”) but also inde-
pendent from the trial research team. The Forensic
Network office will generate the allocation sequences
using an online randomization service (www.sealedenvelo-
pe.com). The researcher completing the baseline assess-
ment will communicate the information necessary for
allocation (site and assessed treatment need) to the
Forensic Network office within 3 days of the participants’
T0 assessment. The Forensic Network office will allocate
the participant and relay this information to the local in-
vestigators by email and keep a randomization record to
audit compliance with the randomization procedure.
Blinding
The assessor administering measures at T0, T1, and T2
assessments will be blind to participants’ allocation status.
Participants and OTRTR facilitators will not be blind to
allocation status. Participants will be asked not to divulge
information about their group to the assessor. Any in-
stances of unblinding will be recorded, and the clinical
outcome analysis will be repeated excluding these partici-
pants to determine the robustness of the findings.
Description of the intervention
On the Road to Recovery
The OTRTR program is comprised of two brief treatment
modules: Awareness & Recovery (A&R) and Looking After
Yourself (LAY). A&R provides psychoeducational material
adapted from Morrison et al. [16] “Think you’re crazy?
Think Again” and from “Coping with Mental Illness” [17],
the original psychoeducation program delivered across the
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Forensic Network. The LAY program’s core aim is to help
patients develop basic coping skills to manage psychological
distress and to develop a “toolkit” for coping with this
distress now and in the future. The protocol is
semi-structured and organized by topics instead of sessions,
which allows the program to flexibly match pace to groups
with greater or lesser need by adjusting the number of ses-
sions. Each topic contains several objectives that are ac-
companied by structured didactic activities, exercises, and
discussion prompts. The program will run over approxi-
mately 12 weeks, with weekly 2-h sessions. Treatment de-
livery is primarily in small groups; however, the program
can also be delivered on an individual basis as part of the
study. Participant attendance and engagement in the treat-
ment sessions will be monitored and recorded. Participants’
RMOs may withdraw a participant from the study and
therefore discontinue OTRTR sessions should there be a
deterioration in participants’ clinical presentation.
OTRTR therapy facilitators will receive group supervi-
sion at least once every four sessions delivered, consist-
ent with the Forensic Matrix governance standards [18].
Facilitators will be provided with standardized recording
documents to closely record the program content deliv-
ered in each session.
Treatment as usual
Participants randomized to the TAU condition will en-
gage in treatment as usual including access to other psy-
chological therapies, with the exception that they do not
attend OTRTR sessions. TAU participants will be ad-
vised they will be offered the OTRTR therapy at a later
stage. Access to and engagement in non-psychological
therapies differs by participating site and individual par-
ticipants. For both groups, we will record the care re-
ceived by participants during the trial to enable a full
description of treatment as usual.
Safety monitoring
We will monitor potential harm from study treatments
experienced by participants by recording the occurrence
of adverse (AE) and serious adverse events (SAE). Any
AE and SAE experienced by participants after consent-
ing to the study will be recorded and reported regardless
of whether it is likely that they are the result of treat-
ment received. The Health Research Authority defines
SAE as an occurrence that (a) results in death, (b) is
life-threatening, (c) requires hospitalization or prolonga-
tion of existing hospitalization, (d) results in persistent
or significant disability or incapacity, and (e) consists of
a congenital anomaly or birth defect. Applying this def-
inition to psychiatric inpatient settings, acts of serious
self-harm, attempted suicide, and suicide would qualify
as a SAE. Events that constitute SAEs are already
routinely collected and monitored at all participating
sites using the Datix incident reporting software.
AEs will be similarly monitored throughout the study.
In the present study, an AE is considered to have occurred
if either of the following takes place: (a) participant is re-
moved from the study at the request of their RMO due to
significant deterioration in the patient’s mental state and/
or behavior and (b) a participant’s global CORE-OM score
(indexes overall psychiatric distress) increases from the
previous assessment to an extent that is both clinically sig-
nificant and reliable (as defined in Evans et al. [19]). All
SAEs and AEs will be recorded, and SAEs will be reported
to a NHS Scotland Research Ethics Committee if and
when they occur.
Data collection and outcome measures
Participant timeline
The trial consists of a 12-week treatment phase with a
3-month (13-week) follow-up phase. As shown in Fig. 1,
participants in both treatment conditions will be
assessed pretreatment at T0, post treatment at T1, and
3-months after post-treatment at T2. A schedule of
study procedures and assessments is detailed in Table 1.
Baseline measures
The following measures will be collected at T0. They
will be used as moderator variables in analysis to identify
mechanisms of change and predict therapy outcomes at
the individual level. We will explore the associations be-
tween these variables and change on the clinical out-
come measures from T0 to T1.
 Demographic data (age, sex, ethnicity, education level)
 Primary and secondary psychiatric diagnoses
 Medication at each assessment point
 Previous participation in psychological therapies
 Time since admission (months)
 Verbal working memory: The Letter-Number
Sequencing subtest of the WAIS-IV [20] will be used
to index verbal working memory. Working memory
was identified as one of several cognitive abilities
which may impact patients’ ability to engage with
and benefit from the On the Road to Recovery
intervention.
Primary outcome measures
Primary study outcomes relate to the feasibility and ac-
ceptability of key trial procedures.
1. Number of eligible participants identified over the
study period will be indexed by the total number of
participants identified across sites who meet eligibility
criteria.
2. Estimate rate of recruitment into the trial
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a. The proportion of eligible patients who agree to
participate (provide consent): We anticipate the
consent refusal rate to fall in the range of 16–37%
based on findings from previous RCTs of
psychological interventions in forensic
populations [21–24]. The adopted benchmark
of success in this study is a consent refusal
rate in this study of less than 37%.
b. The number of participants enrolled into the
study each month during the recruitment
period: As in other ongoing feasibility RCTs
[25], the benchmark of recruitment success is
achieving 80% of target sample size, in this
case recruiting at least 40 participants into
the study.
3. Audit adherence to randomization procedure:
The number of instances where the actual
treatment allocation differed from assigned
allocation. Instances where the participant is
removed from the study by his or her RMO,
who cites a reason related to the allocated
condition as opposed to deterioration in clinical
presentation, will also be considered non-adherence
to the randomization process. Any instances of
non-adherence to the randomization procedure
will cause great concern as to the feasibility of a
future phase III RCT of OTRTR.
4. Estimate completion rate of OTRTR: Proportion
of participants who complete OTRTR. Following
similar studies [26, 27] participants will be
considered to have completed OTRTR if they
attended at least 80% of the planned sessions.
5. Explore reasons for study drop-out during the study
treatment: Participants will have the option of pro-
viding a reason they do not wish to continue with
the study before exiting the study.
6. Completion rate of primary clinical outcome
measures weekly during treatment phase: The
proportion of Birchwood Insight Scale (BIS) and
Coping Styles Questionnaire (CSQ) forms
Fig. 1 Participant flow diagram
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completed as intended each week during the
treatment phase will be calculated.
7. Completion rate of standardized recording forms of
the therapy content delivered by OTRTR therapy
facilitators: Proportion of complete forms will be
calculated.
8. Number of participants lost to follow-up and rea-
sons: Number of participants who withdrew from
the study or who were otherwise lost to follow-up,
with reasons recorded (if provided). The adopted
benchmark of success is a participant attrition rate
of less than 20% at the post-treatment (T1)
assessment.
9. Safety of OTRTR for patients: Descriptive statistics
for frequency of observed AEs and SAEs across
treatment conditions. Adverse events may occur for
reasons independent of the therapy being studied due
to the nature of this clinical population. Safety of
OTRTR will be assessed by comparing the rates of
SAEs and AEs across the two study treatment
conditions. We will also compare the incident rate of
SAEs for study participants to the rate observed for
each participant in the 12 weeks prior to enrolment
in the study. This reference data will be requested
from the local site clinical effectiveness departments
or equivalents following study completion.
10. Average duration of assessment battery at T0, T1,
and T2. Descriptive statistics for length of
assessment. We anticipate the T0 assessment will
last approximately 90 min, and the T1 and T2
assessments 60 min each.
Semi-structured interview
After T2 assessment, each participant will be offered the
opportunity to complete a semi-structured interview
with the researcher. Interviews will solicit participants’
experiences of participating in the study, with a focus on
the treatment phase and assessments. These results will
inform the design of a future RCT of OTRTR.
Secondary outcomes
The secondary outcome measures relate to intended
treatment outcomes of OTRTR. The following measures
will be completed at baseline (T0), post treatment (T1),
and 3-month follow-up (T2) by a researcher blind to the
participant’s allocation status.
1. Birchwood Insight Scale (BIS) [14] is an eight-item
self-report measure of insight. The original study
established BIS total score test-retest reliability
(1-week) as r = 0.90 and internal consistency of
Table 1 Schedule of study procedures and assessments
Study period
Recruitment Baseline (T0) Allocation Treatment
phase
Post treatment
(T1)
3-month
follow-up (T2)
Post-study
Interview (optional)
Procedures
Eligibility screen X
Assess capacity X
Informed consent X
Randomization X
Assessments
Birchwood Insight Scale (BIS) X X (weekly) X X
Coping Styles Questionnaire (CSQ) X X (weekly) X X
Clinical Outcomes in Routine Evaluation
(CORE-OM)
X X X
Rosenberg Self-Esteem Scale (RSE) X X X
Questionnaire on the Process of Recovery
(QPR)
X X X
Brief Psychiatric Rating Scale (BPRS) X X X
Letter-Number Sequencing Test (LNST) X X X
Study entrance questionnaire X
Post-study interview X
Intervention
On the Road to Recovery X
Treatment as usual X
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α = 0.75. The BIS variable used in this study will be
the total score (max 12).
2. Coping Styles Questionnaire (CSQ) [15] is a
60-item self-report measure on the use of maladaptive
and adaptive coping styles. It is comprised of four
subscales, each a unique dimension of coping: rational,
detached, emotional, and avoidance. Test-retest
reliability of the CSQ subscales range from r = 0.70 to
0.80, and the subscale internal consistencies of α = 0.69
to 0.90. The CSQ variable used in this study will be
the total of the two adaptive coping subscales, Rational
and Detached.
3. Clinical Outcomes in Routine Evaluation Outcome
Measure (CORE-OM) [28] is a 34-item self-report
measure of psychological distress that covers four
domains: wellbeing, symptoms/problems, functioning,
and risk to self and others. A global measure of distress
is also calculated across these domains. Good psycho-
metric properties for this measure in non-clinical,
clinical, and forensic populations have been established
[19, 29]. The CORE-OM variable used in this study
will be the 34-item mean score (max 4).
4. Rosenberg Self-Esteem Scale (RSE) [30] is a 10-item
self-report measure of self-esteem. The RSE has an
internal consistency of α = 0.77 and two-week
test-retest reliability of r = 0.85. The total RSE
score will be used (max 30).
5. Questionnaire on the Process of Recovery (QPR)
[31] is a 22-item measure of service user-rated
recovery comprised of an interpersonal and
intrapersonal subscale. The initial validation study
found acceptable two-week test-retest reliability
(intrapersonal subscale r = 0.87, interpersonal
subscale r = 0.77) and internal consistency
(intrapersonal α = 0.94, interpersonal α = 0.77).
The intrapersonal (max 68) and interpersonal
(max 20) subscale scores will be used.
6. Brief Psychiatric Rating Scale (BPRS) [32] is a
clinician/researcher-rated tool used to assess
severity of psychopathology. The 18 items sum to
derive a continuous total score of symptom severity.
The BPRS has good psychometric properties is the
most widely used outcome measure in treatment
studies across populations with severe and
persistent mental illness [33]. The total BPRS score
will be used (max 126).
7. Institution-recorded incidents of physical aggression
and violence: The number of incidents of violence/
aggression, for which the participants are
considered to have responsibility in instigating or
exacerbating, during the study treatment phase and
3-month follow-up period will be compared across
treatment groups. This information will be as par-
ticipants complete T2.
8. Institutional privileges: Changes in institutional
privileges (e.g., increased grounds access,
unsupervised phone calls, and patient outings) will be
recorded for all participants during the study
treatment phase and 3-month follow-up period.
This information will be after participants complete T2.
Weekly clinical measures
Following an intensive longitudinal methods (ILM) ap-
proach [7, 8], the BIS and CSQ will be administered to all
participants each week during the 12-week study treat-
ment phase. Members of the local health care team will
administer these weekly measures and as such they will
not be blind to participants’ treatment allocation status.
Participant and data retention
Participants may withdraw from the study at any time.
We will offer participants who choose to withdraw from
the study the opportunity to share their views and rea-
sons for withdrawal in a post-study interview at the time
of their exit from the study. Participants will be reas-
sured that this is voluntary, and they need have no fur-
ther contact with the research team. Discontinuing
OTRTR therapy will not exclude participants from the
study. Participants who wish to discontinue OTRTR will
be offered the opportunity to participate in the regular
assessment points should they wish. Participants who
withdraw from the research study will be able to con-
tinue (if in OTRTR condition) or commence (if in TAU
condition) OTRTR in the context of their usual care and
treatment. Measures will be clearly prioritized so that in
all assessment batteries primary measures will be admin-
istered prior to secondary minimizing the loss of pri-
mary data should participants withdraw during an
assessment session. The assessment battery may be com-
pleted over two sessions to avoid participant testing
fatigue.
Protocol amendments
Any modifications to the protocol that may impact on
the conduct of the study will require a formal amend-
ment to the protocol. Such amendments will be agreed
upon by the trial research team, and approved by NHS
Scotland Research Ethics Committee prior to implemen-
tation, and notified to the local research committees of
participating organizations in accordance with local reg-
ulations. Minor corrections and/or clarifications to the
protocol, including administrative changes that have no
effect on the way the study is to be conducted, will be
agreed upon by the trial research team and documented.
NHS Scotland Research Ethics may be notified at the
discretion of the trial research team. The ISRCTN trial
registration will also be updated to reflect any protocol
amendments made.
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Data management
All research-generated data will be entered into
password-protected electronic spreadsheets and stored
separately from any participant identifying information.
Participants will be assigned unique study IDs. A master
list matching participant names and study IDs will be
kept in a password-protected excel document and stored
on a secure NHS drive. Only members of the trial re-
search team will have access to the master list. Original
forms (e.g., questionnaires) will be retained for a period
of 3 years after completion of the study, stored securely
on NHS Scotland premises. Anonymized data files may
be retained indefinitely by the research team. To ensure
accurate data collection, the optional post-study inter-
views will be audio recorded and transcribed for qualita-
tive analysis. Audio data will be collected using an
encrypted password-protected audio recorder and
uploaded to a secure NHS drive. Data entry, preparation,
and analysis will be carried out using a bespoke stan-
dardized operating procedure to ensure data integrity.
Statistical analysis
Feasibility and acceptability outcomes
Descriptive statistics will be reported for the key out-
comes on the feasibility data (including mean averages,
standard deviations, and ranges where appropriate). The
number of patients who were eligible, recruitment into
the study, and attrition rates according to each interven-
tion arm will be considered using descriptive statistics
and reported using the CONSORT (Consolidated Stan-
dards of Reporting Trials) flow chart (Fig. 1). Interviews
will be analyzed using thematic analysis [34] to identify
emerging themes within the data.
Clinical outcomes
This study will not be sufficiently powered to determine
treatment efficacy. Evidence of change on clinical out-
comes will be considered with a focus on effect sizes
and reliable change indices over null hypothesis signifi-
cance testing. Effect size estimates (Cohens’ d) will in-
form sample size estimates and inform decisions
regarding the most appropriate outcome measures for
use in a future phase III trial of OTRTR. A modified
intention to treat (ITT) analysis will be used to analyze
change on the outcome measures and derive the effect
size estimates. Therapeutic effect sizes (with 95% confi-
dence intervals) will be derived using linear regression
models comparing T1 scores for the two treatment
arms, with baseline (T0) scores included as covariates.
These analyses will be repeated using between-group
comparison of means at T2 for estimated maintenance
of treatment effects.
Similarly, effect sizes for change in institutional vio-
lence/aggression will be derived. The mean number of
incidents of violence/aggression (recorded by the institu-
tion) measured at post treatment (the mean number of
incidents for duration of study treatment phase, up to
T1) will be compared, controlling for baseline differ-
ences (the mean number of incidents for the 3-months
preceding treatment, up to T0). This analysis will be re-
peated using between-group comparison of mean inci-
dents during follow-up period (record from T1 to T2)
for estimated maintenance of treatment effect.
Changes in institutional privileges (e.g., increased
grounds access, unsupervised phone calls, and patient
outings) will be recorded for participants in both groups
throughout the study treatment phase (T0 to T1) and
follow-up period (T1 to T2). To the researchers’ know-
ledge, this type of outcome has not been previously
studied in treatment evaluations in forensic settings.
This data will be examined primarily to identify the
types of changes that occur and will be used to inform
secondary outcome measure selection and refinement in
a future definitive RCT. Descriptive statistics will be cal-
culated and examined.
An exploratory analysis will also estimate the
individual-level effects on the two primary clinical out-
come measures (Birchwood Insight Scale and the
Coping Styles Questionnaire). This analysis will use the
weekly BIS and CSQ scores collected during the study
treatment phase and analyze change using multilevel
modeling (also referred to as linear mixed effects
modeling). The multilevel approach is advantageous as it
accounts for dependencies among observations
(repeated assessments) nested within individuals and
is flexible in the presence of missing data. The ana-
lysis will reveal individual trajectories (e.g., a time-
course of therapeutic effect) and variability
throughout the treatment period. The model will in-
clude two levels: participants and time (repeated ob-
servations), where time is nested within each
participant. Level of treatment need (assessed at base-
line) will be an additional model parameter. As for
the between-group analyses which aim to estimate
treatment effects, this individual-level treatment ef-
fects analysis will not be sufficiently powered for de-
finitive hypothesis testing and results will be
interpreted with caution.
To our knowledge, there is no recommended Minimal
Clinically Important Difference (MCID) for this study’s
primary outcome measures in forensic psychiatric popu-
lations: the Birchwood Insight Scale and the Coping
Styles Questionnaire. Results from this study will be
used to better understand what an appropriate MCID
would be for this measure in this population. We will
adopt a distribution-based approach, which compares
change on the outcome measure to an index of the mea-
sure’s variability [35, 36]. This approach assumes that
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the outcome measure change score equivalent to a small
effect size (e.g., Cohen’s d = 0.2) would be the MCID.
The MCID will be calculated multiplying 0.2 by the
standard deviation of the outcome measure across the
feasibility study’s entire sample at baseline.
When data is missing, we will record reasons why
missing data occurred, which will help to formulate as-
sumptions about the missing data (e.g., missing at ran-
dom) for the purpose of analysis. We will use a
model-based multiple imputation method to address any
missing outcome, though the exact method will be se-
lected after a survey of the pattern of missing data.
Using the standardized recording forms completed by
the therapy facilitators, each therapy session will be
retrospectively coded as focusing primarily on either (1)
building insight or knowledge of mental health or (2) de-
veloping coping skills. In a separate model restricted to
only OTRTR condition participants, therapy session
focus (measured using the standardized recording forms
completed by the OTRTR facilitators) will be further in-
cluded as an additional predictor of change on the clin-
ical outcome measures.
Data monitoring
Data and safety monitoring issues will be reviewed on a
quarterly basis by the trial research team comprised of
LT, SOR, and LGM. Urgent issues will be addressed as
soon as possible via phone, email, or regular project
meetings that include the trial research team.
A separate formal data monitoring committee will not
be convened for this study due to limited resources and
the feasibility nature of this study.
Determining progression to a full trial
There are specified criteria of success in relation to par-
ticipant consent (refusal < 37%), recruitment (recruit at
least 40 participants) and retention (attrition < 20% at
T1). Should these criteria not be met, we would not pro-
gress to a full trial using the same design. Further feasi-
bility outcomes have been identified as critical for the
decision to pursue a future RCT of OTRTR at all. For
example, if this study finds significant problems with the
application of the randomization procedure (e.g.,
non-adherence at the participating sites), this would in-
dicate a randomized design comparing OTRTR to any
comparison treatment is not feasible and should not be
pursued in this treatment setting. However, most other
potential feasibility or acceptability issues found by this
study could be addressed by modifying the relevant pro-
cedures in a larger RCT. If significant modifications
were indicated, we would consider the need for a second
feasibility trial or an embedded pilot within a full-scale
RCT. Effect size estimates from this feasibility study may
inform the power calculation of a future RCT only if
there have been minor changes to the study design be-
tween the two studies. In this case, when calculating the
necessary sample size of a future trial, we would con-
sider both the effect sizes observed in the feasibility
study (using lower bound 95% confidence interval) and
the minimum clinically important difference in the pri-
mary outcomes.
Dissemination
Trial results will be communicated in conference pre-
sentations, peer-reviewed journal publications and
LGM’s PhD dissertation. Consistent with the University
of Edinburgh Open Access policy, findings will either be
published in Open Access journals or a copy of the pub-
lication will be deposited in an Open Access Repository.
Results will be disseminated in manner that maintains
the confidentiality of individual participants. A summary
of the results will be provided to those participants who
express an interest.
Discussion
Forensic mental health patients are often complex individ-
uals with significant treatment needs relating to their
mental health and risk. Psychological care addressing
these needs must be carefully coordinated and sequenced
often over a period of several years. The OTRTR psycho-
logical intervention program was developed in Scotland as
an initial treatment program for patients near the start of
their recovery journey with forensic mental health ser-
vices. A full evaluation of OTRTR’s effectiveness is neces-
sary to inform evidence-based clinical decision making.
UK Medical Research Council guidance [37, 38] empha-
sizes the need to thoroughly test the feasibility and accept-
ability of key trial procedures prior to commencing a
definitive effectiveness trial.
This study is not without its limitations. The nature of
the comparison condition can greatly affect RCT out-
comes and deserves substantial consideration in the de-
sign phase [39]. While a study-defined comparison
condition was initially preferred by the researchers, this
raised ethical and organizational concerns and we ultim-
ately made a pragmatic decision to utilize a routine care
comparison condition. Details of the care accessed by
study participants will be recorded to enable a full de-
scription of what routine care entailed.
As in many evaluation studies of psychological therap-
ies, there is a difficult balance of protocol fidelity and en-
suring the treatment is responsive to participants’ needs.
The multi-site nature of this evaluation increases the like-
lihood of variation in treatment content delivered
throughout the study. However, we intend to statistically
model the effects of this variation in a novel exploratory
analysis using multilevel modeling. We anticipate that this
method will be useful in allowing a degree of treatment
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flexibility within a rigorous design such as the RCT. More-
over, the ability to statistically model changes in key clin-
ical outcomes to particular elements of the therapy
protocol will add helpful insights and increase the
generalizability of any OTRTR clinical effects observed.
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